bioAffinity Technologies, Inc. Announces Collaboration with Pictor, Inc.

bioAffinity Technologies, Inc. has announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). This partnership aims to integrate bioAffinity's flow cytometry expertise with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles associated with airway inflammation. The collaboration is expected to lower operating costs, improve laboratory efficiency, and reduce testing complexity, facilitating high-throughput testing. bioAffinity Technologies will retain intellectual property rights for tests developed through this collaboration, while Pictor will own new inventions related to its platform. The new diagnostics are intended to advance precision medicine by providing physicians with a comprehensive understanding of the biological processes driving airway inflammation, enabling more informed treatment decisions. The global market for asthma and COPD therapeutics is substantial and projected to grow significantly in the coming years. This partnership is seen as a strategic move to address this growing market with innovative diagnostic tools.